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Abstract 
Screening and early diagnosis are crucial to increase the success of cancer patients’ 
treatments and improve the survival rate. To contribute to this success, distinct 
electrochemical immunosensing platforms were developed for the analysis of the 
ExtraCellular Domain of the Human Epidermal growth factor Receptor 2 (HER2‐ECD) 
through sandwich assays on nanomaterial‐modified screen‐printed carbon electrodes 
(SPCEs). The most promising platforms showed to be SPCEs modified with (i) gold 
nanoparticles (AuNPs) and (ii) multiwalled carbon nanotubes combined with AuNPs. The 
antibody‐antigen interaction was detected using a secondary antibody labelled with 
alkaline phosphatase and 3‐indoxyl phosphate and silver ions as the enzymatic substrate. 
The electrochemical signal of the enzymatically generated metallic silver was recorded 
by linear sweep voltammetry. Under the optimized conditions, linear calibration plots 
were obtained between 7.5 and 50 ng/mL and the total assay time was 2 h 20 min, 
achieving LODs of 0.16 ng/mL (SPCE‐MWCNT/AuNP) and 8.5 ng/mL (SPCE‐AuNP), 
which are well below the established cut‐off value of 15 ng/mL for this cancer biomarker. 
1 Introduction 
Breast cancer, one of the major life‐threatening diseases in woman, is still one of the 
leading causes of oncological deaths 1. Diagnostic techniques for its detection are in 
constant development but are yet far from ideal. Currently medical strategies for 
screening and early detection are based on imagiology tools, namely mammography. 
Although detection is usually achieved with high efficiency, it only allows the 
visualization of the tumour and cannot predict its biological behaviour and evolution 2, 
3. Nevertheless, the evolution of clinical methods for effective detection of breast cancer 
along with the development of non‐invasive and low‐cost in situ techniques can improve 
survival rates and allow personalized patient follow‐up 2, 4. These non‐invasive methods 
are a prominent alternative not only regarding response time but also to minimize the 
patients’ suffering. For this purpose, biosensors have been developed because they 
provide fast analysis and specific recognition. Therefore, their development is in 
continuous expansion and they have widely been applied in point‐of‐care detection 4, 5. 
Current innovations in the field of biosensing lead to accurate results in the analysis of 
tumour biomarkers in patients’ biological fluids such as serum, plasma, whole blood, 
urine, etc. A tumour biomarker is a substance or process indicative of the presence of 
cancer in the body 6. Breast cancer biomarkers can be divided into prognostic, therapeutic 
and diagnostic, and can be detected according to the stage of the cancer 7. Among the 
variety of biomolecules that are approved as tumour biomarkers and accepted for 
diagnosis by medical and clinical teams, there are many biological fluid‐based biomarkers 
of interest for the development of electrochemical biosensors. The main protein breast 
cancer biomarkers for non‐invasive clinical tests are the Human Epidermal growth factor 
Receptor 2 (HER2, ErbB2 or CD340), Cancer Antigen 15‐3 (CA 15‐3) and 
Carcinoembryonic Antigen (CEA). In addition, Circulating Tumour Cells (CTCs) can 
also provide prognostic or predictive information 8, 9. In serum analysis biomarkers that 
shed extracellular domains in the peripheral blood (e. g. HER2) are important analytes 
that can be used as a source of information on the status of the tumour. HER2‐ECD is a 
protein breast cancer biomarker that presents serum levels below 15 ng/mL for healthy 
individuals and can be important for patients’ screening and early detection. HER2 is 
overexpressed in 20–30 % of invasive breast cancer and HER2‐positive breast cancer is 
particularly more aggressive than others 7-9.  
A few electrochemical immunosensing strategies for the detection of HER2 in serum have 
been reported. These strategies are generally based on the modification of the electrode 
surface with nano‐ or micromaterials that can provide improved performances like the 
promotion of electron transfer, signal amplification and the decrease of the limit of 
detection. Furthermore, the use of small‐size transducers, the reasonably short assay times 
and the low reagent/sample volumes are key features for the development of point‐of‐
care devices. Marques et al. (2014) developed a sandwich‐type assay on screen‐printed 
carbon electrodes (SPCEs) which were nanostructured with gold nanoparticles (AuNP) 
to efficiently immobilize anti‐HER2‐ECD capture antibodies through chemisorption 10. 
In a different approach Ravalli et al. developed a label‐free impedimetric biosensor based 
on the immobilization of a terminal cysteine‐modified affibody on gold nanostructured 
graphite screen‐printed electrodes. AuNPs were used in these studies to enhance the 
capture antibody's immobilization and to retain its immunoactivity on the electrode 11. 
Furthermore, the use of nanomaterials, with excellent and reliable physicochemical 
properties, in the sensor's construction increases the electrode's surface area with a 
subsequent increase of sensitivity 12. Arkan et al. proposed an immunosensor based on 
multiwalled carbon nanotubes (MWCNTs) and AuNPs contained in a carbon ionic liquid 
electrode (CILE). Pre‐synthesized AuNPs were grown on the MWCNT‐CILE surface 
through electrodeposition, to form AuNP/MWCNT‐CILE, which is a suitable surface for 
antibody attachment 13. In a distinct approach, Emami et al. employed magnetic iron 
nanoparticles for efficient antibody immobilization on an electrode surface that was 
previously modified with AuNPs/3‐mercaptopropionic acid/cysteamine/poly(ethylene 
glycol)‐maleimide‐3‐aminopropyltrimethoxysilane 14. Moreover, in an analogous but 
simpler methodology, Shamsipur et al. reported the use of 3‐
aminopropyltrimethoxysilane coated magnetite nanoparticles combined with an antibody 
(antiHER2/APTMS‐Fe3O4 NPs) as a platform for efficient HER2 detection 15. The easy 
manipulation, washing and collection of the magnetic nanoparticles using simple magnets 
or magnetic bars are major advantages compared to non‐magnetic assays, reducing cross‐
reactivity and matrix effects. Efficient bioconjugation is largely achieved by using 
magnetic particles comprising a magnetite core (Fe3O4 MNPs) with a non‐magnetic 
coating 5. Al‐Khafaji et al. and Ilkhani et al. used magnetic beads functionalized with 
Protein A to improve the affinity interaction between the biomolecules and to construct 
faster electrochemical bioassays 16, 17. Eletxigerra et al. developed a 
magnetoimmunosensor based on carboxylic acid‐modified magnetic beads. Horseradish 
peroxidase‐labelled secondary antibodies were used and detection was performed through 
amperometry using the hydroquinone (HQ)/H2O2 system 18. Recently, Tallapragada et 
al. proposed a sandwich‐type immunosensor based on the biotin‐avidin chemistry for 
accurate detection of HER2 by using home‐made SPEs 19. Although unmodified 
electrodes were also used for the sensor construction, the total assay time was longer than 
for the previously reported electrochemical immunosensors.  
In this work distinct sensing platforms were studied for the detection of HER2‐ECD: (i) 
SPCEs modified with AuNP, graphene, single‐ or multiwalled carbon nanotubes 
(SWCNT, MWCNT) and (ii) SPCEs modified with graphene, SWCNT‐ or MWCNT in 
combination with AuNPs, forming hybrid nanostructures. These approaches combined 
the advantages of the nanomaterials’ biocompatibilities and the high binding affinity. The 
use of carbon nanomaterials allows better coverage of the SPCEs and the 
electrodeposition of the gold nanoparticles provides a large accessible surface area for 
effective antibody immobilization. The sensing platforms were characterized by scanning 
electron microscopy (SEM) and the electrochemical signals were recorded by linear 
sweep voltammetry (LSV). The detection of the antibody‐antigen interaction in the 
sandwich assay was possible by using a secondary antibody labelled with alkaline 
phosphatase; the electrochemical signal was generated through the oxidation of 
enzymatically deposited metallic silver (a mixture of 3‐indoxyl phosphate (enzymatic 
substrate) and silver ions). In this study the use of different carbon nanomaterials, and 
their combination with AuNPs, with the above‐mentioned detection strategy for the 
detection of HER2‐ECD is reported for the first time. 
2 Experimental 
2.1 Instrumentation 
The electrochemical measurments were carried out using a potentiostat/galvanostat 
(Autolab PGSTAT101, Metrohm Autolab) controlled by the NOVA software package 
(v.1.9; Metrohm Autolab). Screen‐printed carbon electrodes (SPCE, DRP‐110) and a 
specific connector (DRP‐CAC) to interface the electrodes and the 
potentiostat/galvanostat were supplied by DropSens. The SPCEs consisted of working 
(d=4 mm) and counter electrodes made of carbon inks and a silver pseudoreference 
electrode. All the electrodes were discarded after use. The SEM images were obtained by 
using FEI Quanta 400FEG ESEM/EDAX Genesis X4 M equipment, at the “Centro de 
Materiais da Universidade do Porto (CEMUP)”. The histograms were obtained using 
SPSS software, version 20.0 (SPSS Inc., Chicago, Illinois). 
2.2 Reagents 
Albumin from human serum (HSA), albumin from bovine serum (BSA), β‐casein from 
bovine milk, reduced graphene oxide (rGO), carboxylic acid functionalized multiwalled 
carbon nanotubes (MWCNT‐COOH), carboxylic acid functionalized single‐walled 
carbon nanotubes (SWCNT‐COOH), 3‐indoxyl phosphate (3‐IP), N,N‐
dimethylformamide (DMF), ethanolamine, hydrochloric acid, magnesium nitrate 
hexahydrate, nitric acid, streptavidin‐alkaline phosphatase (S‐AP) from Streptomyces 
avidinii, human serum (from male AB clotted whole blood), tetrachoroauric(III) acid and 
tris(hydroxymethyl)aminomethane (Tris), were obtained from Sigma‐Aldrich. Silver 
nitrate was purchased from Alfa Aesar. Rabit IgG monoclonal anti‐human‐HER2‐ECD 
(clone 002) antibody (capture antibody), mouse IgG2a monoclonal biotinylated anti‐
human‐HER2‐ECD (clone 8B5DAC1) antibody (detection antibody), and a recombinant 
HER2‐ECD protein (antigen) were obtained from Sino Biological Inc. 
Ultra‐pure water (resistivity=18.2 MΩ cm) was used and was obtained from a Millipore 
(Simplicity 185) water purification system. The tetrachloroauric(III) acid solution (0.10 
mM) for the electrodeposition of AuNPs was prepared in 0.1 M HCl. Working solutions 
of the capture (C) and detection (D) antibodies and the antigen were prepared in 0.1 M 
Tris‐HNO3 pH 7.4 (buffer 1). The S‐AP solutions were prepared in 0.1 M Tris‐HNO3 pH 
7.4 containing 1 % BSA (buffer 2). The solution containing 3‐IP (1×10−3 M) and silver 
nitrate (4×10−4 M) was prepared in 0.1 M Tris‐HNO3 pH 9.8 containing Mg(NO3)2 
(2×10−2 M) (buffer 3) and stored at 4 °C protected from light. All the buffers and solutions 
were prepared daily.  
2.3 Sensor/Assay Development and Procedure 
Scheme 1 elucidates the different steps of the used sandwich assay.  
 
Scheme 1  
Schematic representation of the electrochemical immunoassay. 
2.3.1 Surface Modification 
Several SPCE‐based immunosensors were tested using different nanomaterials: rGO, 
SWCNT‐COOH, MWCNT‐COOH and AuNPs and combinations of these materials. 
For the carbon nanotubes, (i) the surface of the SPCE was modified by dropping a 1‐μL 
aliquot of an rGO, SWCNT‐COOH or MWCNT‐COOH suspension (dispersed in DMF) 
on the working electrode (WE) of the SPCE which was then dried for 5 minutes at 50 °C. 
The modification of the WE (with or without the carbon nanomaterials) with AuNPs was 
carried out by electrodeposition of gold from 40 μL of a 0.10 mM [AuCl4]
− (in 0.1 M 
HCl) solution according to the procedure described by Martínez‐Paredes et al.: first a 
constant current (−100 μA) was applied for 240 s, and subsequently a constant potential 
(+0.1 V) was applied for 120 s 20. The obtained AuNP‐modified electrodes were rinsed 
with water and dried with nitrogen before use.  
2.3.2 Capture Antibody Immobilization 
The immobilization of the capture antibody on the modified SPCE surfaces was 
performed based on a previous work: (ii) incubation of the SPCE with 10 μL of the 
capture antibody solution (optimized concentration: 25 μg/mL), overnight at 4 °C in a 
humidified chamber. Then the SPCE was washed with buffer 1 before (iii) blocking the 
free surface sites with β‐casein (2 % (m/V) in buffer 1, 40 μL, 30 min) 10.  
2.3.3 Immunoassay 
The optimized assay consisted of the following steps: after washing with buffer 1, (iv) a 
previously prepared mixture (5 min before use) containing the detection antibody (2 
μg/mL), HER2‐ECD and BSA 0.5 % (m/V) was added (40 μL) and left to incubate for 30 
min. The washing step was then repeated with buffer 1, and (v) an aliquot (40 μL) of S‐
AP solution (5×10−10 M) was added for 60 min. Subsequently, a washing step was carried 
out firstly with buffer 1, and then with buffer 3.  
For the electrochemical measurements, (vi) a 40‐μL aliquot of the mixture containing the 
enzymatic substrate (3‐IP, 1.0×10−3 M) and silver nitrate (4.0×10−4 M) was placed on the 
SPCE and after 20 min the electrochemical signal was obtained by LSV using the 
following parameters: potential range: −0.03 V – +0.4 V; scan rate: 50 mV/s.  
2.4 Sample Preparation 
Male human serum was stored at −20 °C and was used as obtained, i. e. serum samples 
were spiked with HER2‐ECD at different concentrations and analysed without further 
treatments. The electrochemical measurements were performed using the above‐
mentioned conditions. 
3 Results and Discussion 
3.1 Sensor/Assay Optimization 
3.1.1 Antibody Concentrations 
The immobilization of the capture antibody on the sensor's surface and the detection 
approach are some of the key features to guarantee the adequate performance of 
immunosensors. According to a previously reported immunosensor for HER2‐ECD 
detection developed in our group 10, AuNPs constitute a good nanomaterial to be used 
for immobilization through chemisorption of monoclonal anti‐human HER2‐ECD 
antibodies (Ab–C). This allowed stable immobilization of the antibodies and led to a high 
sensitivity. In the present study the same procedure was adopted, and the Ab–C and Ab–
D concentrations were studied using SPCE‐AuNP and the following conditions: Ab–C: 
10 and 25 μg/mL; casein: 2 % (m/V); HER2‐ECD: 0 and 50 ng/mL; BSA: 0.5 % (m/V); 
Ab–D: 0.5; 1 and 2 μg/mL; S‐AP: 2.0×10−10 M with BSA 1 % (m/V). The obtained peak 
current intensities are presented in Figure 1(a). As can be observed, the lowest Ab–C 
concentration (10 μg/mL) led to the lowest peak current intensities and the increase of the 
Ab–D concentration led to an increase of the electrochemical signal. However, the results 
also showed that the peak current intensity was similar when the highest Ab–D 
concentration (2 μg/mL) was used for both Ab–C concentrations (10 and 25 μg/mL), 
revealing the importance of the Ab–D concentration on the immunosensor's performance. 
The result can be explained based on the high amount of S‐AP that binds to the detection 
antibody (Ab–D), leading to the signal amplification. Although a good result was 
achieved with the combination of Ab–C 10 μg/mL and Ab–D 2 μg/mL, the best 
performance was obtained when Ab–C 25 μg/mL and Ab–D 2 μg/mL were used. 
Therefore, these concentrations were chosen to proceed with the optimization of the 
immunoassay.  
 
Figure 1  
Optimization of (a) Ab–C and Ab–D concentrations and (b) incubation time of 
HER2+Ab–D (A – 30 min and B – 60 min), enzyme incubation time (I – 30 min and II – 
60 min) and concentration (1 – 2×10−10 M; 2–5×10−10 M and 3–1×10−9 M). (Ab–C (25 
μg/mL), Ab–D (2 μg/mL), casein (2 %), HER2‐ECD (0 (blank) and 50 ng/mL), BSA 
(0.5 %), 3‐IP (1×10−3 M) and Ag+ (4×10−4 M)). 
We previously reported an immunosensor for HER2‐ECD detection, using a gold 
nanoparticle‐modified SPCE as transducer, but using Ab–C 50 μg/mL and Ab–D 1 
μg/mL 10. Comparing the results with the ones obtained in the present study, it can be 
concluded that lower Ab–C concentrations (10 and 25 μg/mL) and a higher Ab–D 
concentration (2 μg/mL) lead to higher peak current intensities.  
 
3.1.2 Incubation Times and Enzyme Concentration 
The influence of the incubation time of the mixture HER2‐ECD+Ab–D (containing 0.5 % 
BSA) was studied using two different times: 30 min (A) and 60 min (B). In addition, three 
concentrations of S‐AP were tested: (1) 2×10−10 M; (2) 5×10−10 M and (3) 1×10−9 M, 
which were incubated for: 30 min (I) and 60 min (II). The influence of these parameters 
was studied using the previously optimized antibody concentrations (Ab–C 2 μg/mL and 
Ab–D 2 μg/mL). The different combinations between the incubation times of the mixture 
and the incubation time and concentrations of S‐AP are shown in Figure 1(b). The 
sequence of the tested parameters is presented according to the incubation time of the 
HER2‐ECD+Ab–D mixture: I.1, II.1, II.2 and II.3 for A and I.1, I.2, I.3 and II.1 for B.  
The results for the shortest incubation times combined with the lowest S‐AP 
concentration (A – I.1) showed a considerable decrease of the peak current intensity. On 
the other hand, the longest incubation times combined with the lowest S‐AP concentration 
(B – II.1) resulted in a considerable improvement of the electrochemical signal. 
Nevertheless, in the latter assay an increase of the blank signal was observed because of 
the increase of non‐specific adsorption on the electrode surface. Regarding the assays in 
which longer incubation of the enzyme (II – 60 min) was used higher signals were 
observed (A – II.1, A – II.2 and A – II.3), but an increase of the enzyme concentration 
increased the blank signal because of the adsorption of S‐AP on the electrode‘s surface, 
indicating that a large amount of enzyme does not bind specifically to the Ab–D. This 
was also observed in B – I.3, although the enzyme incubation time was only 30 min. 
Thus, regardless of the analysis time, the increase of the S‐AP concentration leads to 
higher signal intensity. The combination of the lowest S‐AP concentration and incubation 
time (B – I.1) resulted in a higher analytical signal and a lower blank signal. As a 
compromise between sensitivity and analysis time assay A – II.2 was used in the 
subsequent studies. 
In this work a higher analytical signal and a shorter assay time (2 h 20 min) were obtained 
when compared to the previous work 10.  
3.1.3 Sensing Platform Modification and Characterization 
Distinct gold‐ and carbon‐based nanomaterials can be used in the electrode surface 
modification procedure for HER2‐ECD detection to obtain high sensitivities with reduced 
interferences and low detection limits 10, 11, 13. To compare the results obtained with 
SPCE‐AuNPs as transducer, three carbon‐based nanomaterials were tested: (i) rGO, (ii) 
SWCNT‐COOH and (iii) MWCNT‐COOH. In addition, the combination of rGO, 
SWCNT‐COOH or MWCNT‐COOH with AuNPs were also studied.  
For the surface modification of the SPCEs the carbon nanomaterials’ concentrations were 
optimized (0.5 μg/μL, 1 μg/μL, 2 μg/μL and 4 μg/μL) and 1 μg/μL was chosen because 
of the better sensitivity and precision of the analysis (data not shown). 
The signals obtained using a 50‐ng/mL HER2‐ECD solution were compared with the ones 
obtained with the SPCE‐AuNP (Figure 2).  
 
Figure 2  
Peak current intensities obtained using the tested sensing platforms. 
Between the distinct carbon nanomaterial types, either individually or combined with 
AuNPs, the use of MWCNTs led to the highest signal. However, only when the MWCNT‐
AuNP combination was used an increase of the signal compared with the SPCE‐AuNP 
was observed. Furthermore, the use of the carbon‐based nanomaterials provided lower 
blank signals because coating the surface of the electrode with these materials is generally 
more effective, thereby reducing the interference of the sample matrix or the excess of 
antibodies and/or enzymes which have not been effectively removed in the washing step 
and which have no binding affinity to these materials. On the other hand, gold 
nanomaterials allow a more efficient immobilization of biomolecules, as can be observed 
by the increase of the signal. 
Scanning electron microscopy (SEM) was used to characterize the modifications of the 
SPCE surfaces that provided the highest electrochemical signals. The electrodeposited 
AuNPs presented a normal distribution and a circular shape with an average diameter of 
17.9±4.2 nm (Figure 3(a)). When the AuNPs were electrodeposited on the SPCE 
previously modified with carbon nanotubes an increase in their size was observed 
(average diameter: 26.1±5.6 nm) because the surface of the SPCE was completely 
covered with the carbon nanotubes (Figure 3(b)).  
 
Figure 3  
SEM images and respective histograms of (a) SPCE‐AuNP and (b) SPCE‐
MWCNT/AuNP. 
3.2 Analytical Performance and Applicability 
The analytical responses toward different HER2‐ECD concentrations using the best 
surface modifications (AuNP and MWCNT/AuNP) were first tested in buffer. Solutions 
of HER2‐ECD (concentrations between 7.5 and 100 ng/mL) were analysed and the 
working ranges were established (data not shown). Then the sensing strategies were tested 
in spiked human serum samples. The linear relationship between ip and [HER2 ECD] 
(7.5–50 ng/mL) was established for SPCE‐AuNP (i p=1.22±0.07 [HER2‐
ECD]+27.6±2.1, r=0.995) and for the SPCE‐MWCNT/AuNP (i p=2.31±0.13 [HER2‐
ECD]+9.03±4.27, r=0.997. This shows that the SPCE‐MWCNT/AuNP provided the 
highest sensitivity. The limits of detection (LOD) and quantification (LOQ) were 
calculated from the respective calibration plots using the equations: LOD=3 sblank/m and 
LOQ=10 sblank/m where sblank is the standard deviation of the blank signal and m is the 
slope of the calibration plot. The LODs were 8.5 ng/mL for the SPCE‐AuNP and 0.16 
ng/mL for the SPCE‐MWCNT/AuNP. Considering the cut‐off value for HER2‐ECD (15 
ng/mL), the sensing strategies provided LODs that were below this value, indicating their 
usefulness for HER2‐ECD detection in the initial stage of the cancer. Representative 
voltammograms in the linear range and the calibration plots are presented in Figure 4. 
Additional figures of merit are presented in Table 1.  
 
Figure 4  
(a) Examples of linear sweep voltammograms for the analysis of HER2‐ECD: 0, 7.5, 15, 
25, 35 and 50 ng/mL, (b) calibration plots in spiked human serum using SPCE‐AuNP and 
SPCE‐MWCNT/AuNP. 
Table 1. Analytical characteristics of the developed electrochemical biosensors for the 
analysis of HER2‐ECD in Human serum samples.  




Concentration interval (ng/mL) 7.5–50 7.5–50 
Correlation coefficient (r) 0.995 0.997 
Slope (m) (μA/(ng/mL) 1.22 2.31 
Standard deviation of the slope (Sm) 
(μA/(ng/mL) 
0.07 0.13 
Intercept (b) (μA) 27.6 9.03 
Standard deviation of the intercept (Sa) (μA) 2.1 4.27 
Standard deviation of the linear regression 
(Sy/x) 
2.30 3.97 
Standard deviation of the method (Sx0) 1.9 1.7 
Coefficient of variation of the method (Vx0) 
(%) 
7.1 5.8 
Limit of detection (LOD) (ng/mL) 8.5 0.16 
Limit of quantification (LOQ) (ng/mL) 28 0.54 
The precision of the results, in terms of repeatability and intermediate precision, using 
the distinct sensing platforms was tested by analysing a 50‐ng/mL HER2‐ECD solution 
in triplicate on the same day and different days. Relative standard deviations (RSD) of 
2.8 % and 6.5 % for the SPCE‐AuNP, 2.5 % and 7.6 % for the SPCE‐MWCNT/AuNP 
were obtained, indicating that all the sensing platforms provided precise results. 
Because the SPCE‐MWCNT/AuNP provided the highest sensitivity, recovery studies 
with this platform were performed using spiked serum samples. The results for three 
replicates of added 7.5, 15 and 50 ng/mL HER2‐ECD were found to be 8.25±0.67 ng/mL, 
12.4±0.98 ng/mL and 45.6±1.34 ng/mL, with average recoveries of 110 %, 83 % and 
91 %, respectively. These values indicated that the SPCE‐MWCNT/AuNP provided 
accurate results. 
The selectivities of the SPCE‐AuNP and SPCE‐MWCNT/AuNP were tested through the 
analysis of other biomarkers and possible serum interferents: another breast cancer 
biomarker (CA 15‐3), a biomarker of kidney function (cystatin C) and human serum 
albumin (HSA). Solutions of these proteins of 30 U/mL (CA 15‐3), 565 ng/mL (cystatin 
C) and 35 mg/mL (HSA) were tested. These concentrations were chosen based on the 
values that can be expected in real situations (except for CA 15‐3, which can vary greatly 
in the case of cancer patients). The peak current intensities obtained for these non‐target 
proteins are shown in Figure 5. As can be observed, the signals were significantly 
different from the ones obtained for HER2‐ECD, confirming the selectivity of the 
different sensing platforms.  
 
Figure 5  
Results obtained in the selectivity studies using the developed sensing strategies. 
In Table 2 some characteristics of electrochemical immunosensors and immunoassays 
reported for HER2 analysis in serum samples are presented. Although in label‐free assays 
the analysis times are shorter than in the sandwich‐type assays, the time required for the 
electrode surface modification and subsequent incubation of the capture antibody is 
considerably higher. From the comparison of the analytical performances of the 
immunomagnetic assays 14-18 with the immunosensors 10, 11, 13, 19 can be concluded 
that when magnetic beads are used as sensing platform, shorter linear ranges and slightly 
lower LODs were obtained. This indicates that the use of magnetic particles and the 
detection strategy optimized in this work is promising. Nevertheless, all the reported 
sensing strategies provide limits of detection below the cut‐off value for HER2 (15 
ng/mL), which means that they could be useful in the clinical setting.  
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In the strategies studied in our work generally similar linear ranges and analysis times 
were obtained and the LODs were comparable with the ones reported in the previous 
works, except for the studies in which magnetic particles were applied. Nevertheless, the 
best sensitivity was obtained for the SPCE‐MWCNT/AuNP which is probably due to the 
good electrode surface coverage of the carboxylic acid functionalized MWCNTs and 
subsequent electrodeposition of gold, which allows suitable antibody immobilization. 
4 Conclusions 
To improve the electrochemical analysis of HER2‐ECD, the modification of the surface 
of SPCEs with gold (AuNPs) and carbon nanomaterials (rGO, SWCNT‐COOH and 
MWCNT‐COOH) and combinations of these materials were tested. Among the carbon‐
based nanomaterials, MWCNT‐COOH provided the highest sensitivity. The combination 
of MWCNT‐COOH with AuNPs revealed the highest sensitivity. The antibody 
concentrations were optimized and used to develop biosensing strategies on SPCE‐AuNP 
and SPCE‐MWCNT/AuNP, achieving limits of detection well below the cut‐off value for 
this breast cancer biomarker. 
Spiked human serum samples were used to test the sensing platforms’ applicability and 
the selectivity was confirmed through the analysis of other biomarkers and possible serum 
interferents: Human Serum Albumin (HSA), Cancer Antigen 15‐3 (CA 15‐3) and 
Cystatin C, observing no significant interference of these proteins in the analysis. 
Like this, the developed sensing strategies could be an alternative for the analysis of 
HER2‐ECD. 
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